About: Combined Resection and Radiofrequency Ablation for Advanced Hepatic Malignancies: Results in 172 Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Combined Resection and Radiofrequency Ablation for Advanced Hepatic Malignancies: Results in 172 Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Combined Resection and Radiofrequency Ablation for Advanced Hepatic Malignancies: Results in 172 Patients
Creator	Izzo, Francesco Pawlik, Timothy Cohen, Deborah Curley, Steven Morris, Jeffery
Source	PMC
abstract	Background: Resection combined with radiofrequency ablation (RFA) is a novel approach in patients who are otherwise unresectable. The objective of this study was to investigate the safety and efficacy of hepatic resection combined with RFA. Methods: Patients with multifocal hepatic malignancies were treated with surgical resection combined with RFA. All patients were followed prospectively to assess complications, treatment response, and recurrence. Results: Seven hundred thirty seven tumors in 172 patients were treated (124 with colorectal metastases; 48 with noncolorectal metastases). RFA was used to treat 350 tumors. Combined modality treatment was well tolerated with low operative times and minimal blood loss. The postoperative complication rate was 19.8% with a mortality rate of 2.3%. At a median follow-up of 21.3 months, tumors had recurred in 98 patients (56.9%). Failure at the RFA site was uncommon (2.3%). A combined total number of tumors treated with resection and RFA >10 was associated with a faster time to recurrence (P = .02). The median actuarial survival time was 45.5 months. Patients with noncolorectal metastases and those with less operative blood loss had an improved survival (P = .03 and P = .04, respectively), whereas radiofrequency ablating a lesion >3 cm adversely impacted survival (HR = 1.85, P = .04). Conclusions: Resection combined with RFA provides a surgical option to a group of patients with liver metastases who traditionally are unresectable, and may increase long-term survival.
has issue date	2003-01-01(xsd:dateTime)
bibo:doi	10.1245/aso.2003.03.026
bibo:pmid	14597445
has license	no-cc
sha1sum (hex)	1cdad2e9c9672251af14de4558fa968e6cce8bce
schema:url	https://doi.org/10.1245/aso.2003.03.026
resource representing a document's title	Combined Resection and Radiofrequency Ablation for Advanced Hepatic Malignancies: Results in 172 Patients
has PubMed Central identifier	PMC7101740
has PubMed identifier	14597445
schema:publication	Ann Surg Oncol
resource representing a document's body	covid:1cdad2e9c9672251af14de4558fa968e6cce8bce#body_text
is schema:about of	named entity 'UNRESECTABLE' named entity 'PATIENTS' named entity 'NOVEL' named entity 'hepatic' named entity 'Resection' named entity 'combined' named entity 'resection' named entity 'Radiofrequency Ablation' named entity 'tumors' named entity 'lesion' named entity 'necrosis' named entity 'hepatic vein' named entity 'fluoropyrimidine' named entity 'liver function' named entity 'long-term' named entity 'hepatic' named entity 'electrode' named entity 'lobectomy' named entity 'ocular melanoma' named entity 'tumor' named entity 'United States' named entity 'ablated' named entity 'univariate analysis' named entity 'liver' named entity 'lesion' named entity 'lesion' named entity 'tumor biology' named entity 'tumors' named entity 'long-term' named entity 'tumors' named entity 'Cox proportional hazards model' named entity 'histologically' named entity 'tumors' named entity 'survival rate' named entity 'multisystem organ failure' named entity 'hepatic' named entity 'blood loss' named entity 'hepatic disease' named entity 'median follow-up' named entity 'histology' named entity 'United States' named entity 'perfused' named entity 'hepatic' named entity 'tumors' named entity 'tumor' named entity 'adjuvant' named entity 'tumors' named entity 'five-year survival rates' named entity 'carcinomas' named entity 'tumors' named entity 'tumors' named entity 'laboratory tests' named entity 'univariate analysis' named entity 'tumor' named entity 'tumor' named entity 'hepatic' named entity 'Resection' named entity 'metastases' named entity 'ablation' named entity 'serum' named entity 'hepatic' named entity '5.5' named entity 'treatment modality' named entity 'liver' named entity 'MRI imaging' named entity 'metastases' named entity 'tumors' named entity 'ablative' named entity 'liver metastases' named entity 'chemotherapy' named entity 'tumors' named entity 'metastatic' named entity 'liver resection' named entity 'blood loss' named entity 'follow-up' named entity 'irinotecan' named entity 'stomach'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software